Join researchers, policymakers and Andean community voices at CEU Vienna to explore coca’s cultural, scientific and political dimensions — and what the WHO’s review means for global drug governance.
White et al. argue that scientific, cultural and legal evidence clearly distinguishes coca from cocaine — and that global drug policy must correct this long-standing misclassification rooted in colonial bias.
Traditional coca leaf producers and consumers from Peru reject their government’s stance before the WHO, urging the organisation to deschedule coca, recognise its cultural and medicinal uses, and support research and rights-based policies
Bolivia's campaign to remove the coca leaf from the list of the world’s most dangerous drugs highlights the plant's cultural, medicinal and economic importance — and its potential to reshape global drug policy.
The New Zealand Drug Foundation urges reform of outdated drug laws, calling for decriminalisation, Māori-led health approaches and investment in harm reduction to build safer, fairer, evidence-based policies for Aotearoa New Zealand.
This dialogue at SOAS explores the coca leaf beyond prohibition — as a bridge between Indigenous knowledge, environmental justice, and drug policy reform. Featuring voices from Colombia and beyond.
The Human Rights Council’s latest resolution on drug policy marks a turning point, reaffirming that drug control is a human-rights issue, and calling for person-centred, inclusive, and accountable approaches.
Explicit recognition of widespread public health harms of repressive control efforts could positively influence expert recommendation on the schedule of the coca leaf.
UNDP charts a rights- and development-centred turn in drug policy, prioritising decriminalisation, harm reduction, equity-led transitions, and practical pathways to responsibly regulate some drug markets.
IDPC and five other organisations called on the UN to correct historic injustices, respect Indigenous perspectives, and address the harmful impacts of current drug policies.
The WHO ECDD reviews the coca leaf’s chemistry, pharmacology, and uses, noting potential therapeutic effects, low toxicity, and weak evidence of dependence potential.